Streetbeat News

ELV

Elevance Health Inc.

https://www.elevancehealth.com

Industry

Medical - Healthcare Plans

Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Open

405.00

Mkt cap

93B

Volume

2.6M

High

408.58

P/E Ratio

14.58

52-wk high

567.26

Low

398.69

Div yield

0.02

52-wk low

397.98

Elevance Health reported a Q4 benefit expense ratio of 89.2%, improving by 50 basis points from Q4 2022, and an annual benefit expense ratio of 87%, which is an improvement of 60 basis points from the previous year.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 11:03 am

Elevance Health (NYSE:ELV) reported Q4 adjusted EPS of $5.65, surpassing the $5.64 estimate, marking a 15.78% increase from last year's $4.88. Sales reached $42.45B, exceeding the $42.09B estimate, up 7.03% from the previous year.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 11:01 am

Earnings reports for January 24, 2024, are scheduled for a wide range of companies across various industries. The reports include a mix of expected profits and losses, with key players like Freeport-McMoRan, General Dynamics, ASML Holding, and Tesla among those reporting. Investors will be closely watching these earnings releases to gauge company performance and sector health.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 10:11 am

Elevance Health (NYSE:ELV) is expected to release its quarterly earnings report on January 24, 2024, with an estimated EPS of $5.64. Investors are looking for an earnings beat and positive guidance for future growth. Historically, Elevance Health's stock price has shown mixed reactions to past earnings performances. Currently, shares are down 4.86% over the last 52 weeks, indicating a bearish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 7:00 pm

Elevance Health (NYSE:ELV) has seen a 13.04% decrease in short interest since its last report, with 1.88 million shares sold short, representing 0.8% of its float. The average time to cover these short positions is 2.06 days. A decrease in short interest can indicate a more bullish sentiment among investors. Elevance Health's short interest is below its peer group average of 3.54%.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 1:45 pm

U.S. stock indexes hit all-time highs with the S&P 500 reaching 4,850 points, Nasdaq 100 at 17,365, and the Dow Jones briefly touching 38,000. Small caps outperformed, with the iShares Russell 2000 ETF (IWM) rising 1.7%. Treasury yields eased, benefiting the iShares 20+ Year Treasury Bond ETF (TLT), which rose 0.6%. Gold fell, oil prices soared, and Bitcoin tumbled. SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones (DIA), and Invesco QQQ Trust (QQQ) all rose 0.3%. Industrials Select Sector Fund (XLI) outperformed, while Utilities Select Sector Fund (XLU) lagged. AMD fell after a downgrade, Tesla dropped due to a stalling EV outlook, ADM plummeted amid an investigation, GILD fell after a trial failure, and WDC rose on business separation plans. Key earnings reports are anticipated this week from companies like GE, JNJ, RTX, PG, VZ, LMT, NFLX, TXN, ISRG, and more.

Portfolio Pulse from Piero Cingari

January 22, 2024 | 6:35 pm

Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Elevance Health (NYSE:ELV) and maintained a price target of $547.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 5:21 pm

In Friday's pre-market session, several healthcare stocks experienced significant movements. Jaguar Health (JAGX) saw the largest increase, with shares up by 37.0% to $0.15, while Estrella Immunopharma (ESLA) led the decliners, falling 14.9% to $0.86. Other notable gainers include Jin Medical International (ZJYL), Aileron Therapeutics (ALRN), Aditxt (ADTX), Akso Health Group (AHG), and DarioHealth (DRIO). On the losing side, MAIA Biotechnology (MAIA), Elevance Health (ELV), Stereotaxis (STXS), Humana (HUM), and Grifols (GRFS) also saw their share prices drop.

Portfolio Pulse from Benzinga Insights

January 12, 2024 | 1:06 pm

Elevance Health (NYSE:ELV) has delivered an average annual return of 18.26% over the past 15 years, outperforming the market. A $1000 investment in ELV 15 years ago would be worth $11,719.48 today. The company's current market capitalization stands at $112.79 billion.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 2:00 pm

Elevance Health has reportedly acquired Paragon Infusion, a specialty infusion services provider, for over $1 billion. This acquisition is part of Elevance's strategy to expand its healthcare services and capabilities.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 6:33 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.